Drug General Information |
Drug ID |
D05RII
|
Former ID |
DNC006738
|
Drug Name |
3-(1-benzylpiperidin-4-yl)-5-chloro-1H-indole
|
Drug Type |
Small molecular drug
|
Indication |
Discovery agent
|
Investigative |
[1]
|
Structure |
|
Download
2D MOL
3D MOL
|
Formula |
C20H21ClN2
|
Canonical SMILES |
C1CN(CCC1C2=CNC3=C2C=C(C=C3)Cl)CC4=CC=CC=C4
|
InChI |
1S/C20H21ClN2/c21-17-6-7-20-18(12-17)19(13-22-20)16-8-10-23(11-9-16)14-15-4-2-1-3-5-15/h1-7,12-13,16,22H,8-11,14H2
|
InChIKey |
NRIVFQIOYWIUPX-UHFFFAOYSA-N
|
PubChem Compound ID |
|
Target and Pathway |
Target(s) |
Kappa-type opioid receptor |
Target Info |
Inhibitor |
[1]
|
Nociceptin receptor |
Target Info |
Inhibitor |
[1]
|
Mu-type opioid receptor |
Target Info |
Inhibitor |
[1]
|
KEGG Pathway
|
Neuroactive ligand-receptor interactionhsa04080:Neuroactive ligand-receptor interactionhsa04080:Neuroactive ligand-receptor interaction
|
Estrogen signaling pathway
|
Morphine addiction
|
NetPath Pathway
|
TCR Signaling Pathway
|
PANTHER Pathway
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
Opioid prodynorphin pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
Enkephalin release
|
Pathway Interaction Database
|
IL4-mediated signaling events
|
Reactome
|
Peptide ligand-binding receptors
|
G alpha (i) signalling eventsR-HSA-375276:Peptide ligand-binding receptors
|
G alpha (i) signalling events
|
WikiPathways
|
GPCRs, Class A Rhodopsin-like
|
Peptide GPCRs
|
GPCR ligand binding
|
GPCR downstream signalingWP455:GPCRs, Class A Rhodopsin-like
|
GPCR downstream signalingWP69:TCR Signaling Pathway
|
Opioid Signalling
|
GPCR downstream signaling
|
References |
REF 1 | Bioorg Med Chem Lett. 2006 Jul 1;16(13):3524-8. Epub 2006 Apr 24.3-(4-Piperidinyl)indoles and 3-(4-piperidinyl)pyrrolo-[2,3-b]pyridines as ligands for the ORL-1 receptor. |